What is Zacks Research’s Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on Tuesday, March 24th. Zacks Research analyst J. Vandermosten now forecasts that the biopharmaceutical company will earn ($1.40) per share for the year, down from their previous estimate of ($1.07). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.65) EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Trading Up 2.5%

Shares of ACHV opened at $2.89 on Friday. The company’s fifty day simple moving average is $4.38 and its 200-day simple moving average is $4.29. The company has a market cap of $153.83 million, a P/E ratio of -2.22 and a beta of 1.81. The company has a current ratio of 4.39, a quick ratio of 5.14 and a debt-to-equity ratio of 0.52. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $6.03.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC bought a new stake in shares of Achieve Life Sciences during the first quarter valued at approximately $32,000. Franklin Resources Inc. increased its holdings in Achieve Life Sciences by 81.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock worth $10,077,000 after purchasing an additional 2,000,079 shares during the period. Stonepine Capital Management LLC purchased a new position in Achieve Life Sciences during the 2nd quarter worth $753,000. Qube Research & Technologies Ltd bought a new stake in Achieve Life Sciences during the 2nd quarter valued at $232,000. Finally, Raymond James Financial Inc. raised its position in Achieve Life Sciences by 57.1% during the 2nd quarter. Raymond James Financial Inc. now owns 295,058 shares of the biopharmaceutical company’s stock valued at $667,000 after purchasing an additional 107,218 shares in the last quarter. 33.52% of the stock is currently owned by institutional investors.

Key Stories Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and set a $12 price target, raising visibility on upside if cytisinicline gains FDA approval and commercial traction; the firm also published short‑term EPS forecasts tied to ongoing development. HC Wainwright Buy Rating
• Positive Sentiment: Unusually large retail/institutional call option purchases were reported, signaling speculative bullish positioning that can amplify near‑term upside and volatility. Investors Purchase Call Options
• Positive Sentiment: Publication in Nicotine & Tobacco Research linked cytisinicline’s receptor selectivity to low nausea and favorable tolerability — data that supports the drug’s safety profile and could aid regulatory review and prescriber adoption. GlobeNewswire Publication
• Positive Sentiment: Analyst/industry commentary highlights an upcoming FDA PDUFA date (June 20, 2026) for cytisinicline and plans to start a Phase 3 vaping‑cessation trial (ORCA‑V2) in 1H 2026 — both are key milestones that could create major value inflection points if positive. Seeking Alpha PDUFA / Vaping Expansion
• Neutral Sentiment: Company Q4 2025 earnings call and accompanying summaries reviewed program timelines, manufacturing partnerships and commercialization planning — useful for modeling but no new regulatory decision was announced on the call. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 2025 results showed a slight EPS miss (reported -$0.28 vs. consensus -$0.27) and the company remains unprofitable with negative forward EPS consensus; until regulatory approval and commercial revenue arrive, cash burn and dilution risk remain headwinds. Q4 2025 Earnings Call Transcript

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.